CD4 and COVID-19: This could be one of the reasons explaining why RTX + bendamustine–treated patients showed a higher propensity to develop more severe COVID-19, even if their percentage of Spike-specific CD4+ T-cell response was comparable to RTX + other chemotherapy–treated patients.